The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Abstract
We have investigated the pharmacologic effects of a new bisphosphonate compound, CGP 42′446 [2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonate], on bone metabolism. The compound exhibited potent inhibitory activity on the bone resorption induced by 1,25-dihydroxyvitamin D3 both in vivo in the thyroparathyroidectomized rat (ED50 0.072 μg/kg SC) and in vitro in mouse calvarial cultures (IC50 0.002 μM). A comparison of the in vivo and in vitro inhibitory potencies of a total of nine bisphosphonates revealed an excellent correlation between the two assays (r = 0.97). CGP 42′446 also potently inhibited calvarial bone resorption induced by parathyroid hormone (1–34), parathyroid hormone-related protein (1–34), and recombinant human interleukin-1β. Short-term treatment of growing rats with CGP 42′446 dose-dependently increased the radiographic density of the tibial proximal metaphysis (ED50 1.7 μg/kg SC) as well as increasing the calcium and hydroxyproline content of femoral trabeculae (ED50 values 0.17 and 1.1 μg/kg SC, respectively), but there was no detectable effect on cortical bone. On a molar basis in this range of in vivo screening assays, CGP 42′446 was between 940-fold (thyroparathyroidectomized rat) and 87-fold (rat femoral trabecular calcium content) more potent than pamidronate. It is concluded that CGP 42′446 is a promising new, highly potent bisphosphonate for the suppression of the increased bone resorption associated with various diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saikku, P., Mattila, K., Nieminen, M. S., Huttunen, J. K., Leinonen, M., Ekman, M.-R., Mäkelä, P. H., & Valtonen, V (1988) · The Lancet · doi:10.1016/s0140-6736(88)90741-6 · Cited by 1,964
Handbook of Experimental Pharmacology.
Meakin, J. W. (1971) · Archives of Internal Medicine · doi:10.1001/archinte.1971.00310230151026 · Cited by 1,959
CENTRAL OBESITY AND CORONARY HEART DISEASE IN MEN
Donahue, R., & Abbott, R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91357-2 · Cited by 818
A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues
Jamall, I. S., Finelli, V. N., & Que Hee, S. S. (1981) · Analytical Biochemistry · doi:10.1016/0003-2697(81)90261-x · Cited by 518
Schenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Gowen, M., & Mundy, G. R. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2478 · Cited by 476
The acute-phase response after bisphosphonate administration
Adami, S., Bhalla, A. K., Dorizzi, R., Montesanti, F., Rosini, S., Salvagno, G., & Lo Cascio, V. (1987) · Calcified Tissue International · doi:10.1007/bf02556671 · Cited by 357
Russell, R. G. G., Mühlbauer, R. C., Bisaz, S., Williams, D. A., & Fleisch, H. (1970) · Calcified Tissue Research · doi:10.1007/bf02196199 · Cited by 341
Schenk, R., Eggli, P., Fleisch, H., & Rosini, S. (1986) · Calcified Tissue International · doi:10.1007/bf02555748 · Cited by 315
Structure-activity relationships of various bisphosphonates
Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983) · Calcified Tissue International · doi:10.1007/bf02405012 · Cited by 306
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060915 · Cited by 239
Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone
Gunness-Hey, M., & Hock, J. M. (1984) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(84)90026-2 · Cited by 216
HERPES-VIRUS IMMUNITY AND ACUTE GRAFT-VERSUS-HOST DISEASE
Gratama, J. W., Stijnen, T., Weiland, H. T., Hekker, A. C., De Gast, G. C., Zwaan, F. E., Weijers, T. F., D'Amaro, J., The, T. H., & Vossen, J. M. J. J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92088-5 · Cited by 210
van Holten-Verzantvoort, A. T., Bijvoet, O. L. M., Hermans, J., Harinck, H. I. J., Elte, J. W. F., Beex, L. V. A. M., Cleton, F. J., Kroon, H. M., Vermey, P., Neijt, J. P., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92555-4 · Cited by 202
FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASE
Boyce, B. F., Fogelman, I., Ralston, S., Smith, L., Johnston, E., & Boyle, I. T. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92272-4 · Cited by 196
RENAL FAILURE ASSOCIATED WITH INTRAVENOUS DIPHOSPHONATES
Bounameaux, H., Schifferli, J., Montani, J.-P., Jung, A., & Chatelanat, F. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91465-4 · Cited by 193
Hypercalcemia of malignancy revisited.
Mundy, G. R. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113555 · Cited by 190
Organ Culture in Biomedical Research
Franks, L. M. (1976) · Europe PMC (PubMed Central) · Cited by 172
Flanagan, A. M., & Chambers, T. J. (1991) · Calcified Tissue International · doi:10.1007/bf02555852 · Cited by 171
Effect of Disodium Ethane-l-Hydroxy-1, 1 - Diphosphonate on Bone Formation
King, W. R., Francis, M. D., & Michael, W. R. (1971) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-197107000-00021 · Cited by 170
INTRAVENOUS CLODRONATE IN THE TREATMENT AND RETREATMENT OF PAGET'S DISEASE OF BONE
Yates, A. J. P., Gray, R. E. S., Urwin, G. H., et al. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92253-6 · Cited by 127
The long-term skeletal effects of EHDP in dogs
Flora, L., Hassing, G. S., Cloyd, G. G., Bevan, J. A., PARFITT, A. M., & Villanueva, A. R. (1981) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(81)90045-x · Cited by 95
Treatment of paget's disease of bone with aminohydroxybutylidene bisphosphonate
O’Doherty, D. P., Bickerstaff, D. R., McCloskey, E. V., Hamdy, N. A. T., Beneton, M. N. C., Mian, M., Kanis, J. A., & Harris, S. (1990) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650050510 · Cited by 72
Papapoulos, S. E., Hoekman, K., Löwik, C. W. G. M., Vermeij, P., & Bijvoet, O. L. M. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040518 · Cited by 67
Fukayama, S., BOSMA, T. J., GOAD, D. L., Voelkel, E. F., & Tashjian, A. H. (1988) · Endocrinology · doi:10.1210/endo-123-6-2841 · Cited by 62
Cited by
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Metadata
- Authors
- Green, J. R., Müller, K., & Jaeggi, K. A.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-05-01
- Volume
- 9
- Issue
- 5
- Pages
- 745-751
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2074890088
- Cited by
- 415
- References
- 25
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.